ABVC BioPharma, Inc.
ABVC
Rank in Stocks
#25345
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on... ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.
Share Price
$0.9921
Last synced: 2026-11-11
Market Cap
$26.45M
Change (1 day)
0.21%
Change (1 year)
-64.57%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade ABVC BioPharma, Inc. (ABVC)
Category
Healthcare
EPS for ABVC BioPharma, Inc. (ABVC)
EPS as of June 2026 TTM: $-0.29
According to ABVC BioPharma, Inc.'s latest financial reports, its current EPS (TTM) is $-0.29. At the end of 2025 the company had an EPS of $-0.39, an increase over its 2024 EPS of $-0.42.
EPS history for ABVC BioPharma, Inc. from 2002 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.29 | -25.64% |
| 2025 | $-0.39 | -7.14% |
| 2024 | $-0.42 | -76.67% |
| 2023 | $-1.80 | -65.38% |
| 2022 | $-5.20 | 1.96% |
| 2021 | $-5.10 | 2.00% |
| 2020 | $-5.00 | 138.10% |
| 2019 | $-2.10 | -55.22% |
| 2018 | $-4.69 | 31.01% |
| 2017 | $-3.58 | -64.94% |
| 2016 | $-10.21 | 88,682.61% |
| 2015 | $-0.01 | -99.99% |
| 2014 | $-126.07 | -89.87% |
| 2013 | $-1.24K | -84.64% |
| 2012 | $-8.10K | -86.81% |
| 2011 | $-61.42K | -56.07% |
| 2010 | $-139.82K | -40.64% |
| 2009 | $-235.55K | 327.94% |
| 2008 | $-55.04K | -56.21% |
| 2007 | $-125.70K | 18,211.73% |
| 2006 | $-686.46 | -4.77% |
| 2005 | $-720.81 | -1,150.44% |
| 2004 | $68.62 | -160.60% |
| 2003 | $-113.23 | 26.81% |
| 2002 | $-89.29 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -5,500.00% |
US
|
|
| $-7.07 | 2,337.93% |
US
|
|
| $-5.29 | 1,724.14% |
AU
|
|
| $12.88 | -4,541.41% |
BE
|
|
| $21.56 | -7,534.48% |
NL
|
Questions about ABVC BioPharma, Inc.'s earnings per share (EPS)
What is ABVC BioPharma, Inc.'s earnings per share (EPS)?
ABVC BioPharma, Inc.'s earnings per share (EPS) over the last twelve months is $-0.29, as of Jun 2026.
What was ABVC BioPharma, Inc.'s earnings per share (EPS) in 2025?
In 2025, ABVC BioPharma, Inc.'s earnings per share (EPS) was $-0.39, compared with $-0.42 in 2024.
How has ABVC BioPharma, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, ABVC BioPharma, Inc.'s earnings per share (EPS) was highest in 2025 ($-0.39) and lowest in 2022 ($-5.20).
How does ABVC BioPharma, Inc.'s earnings per share (EPS) compare with similar companies?
ABVC BioPharma, Inc.'s earnings per share (EPS) ($-0.29) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.